Med.IQ
11 jun, 2025
On May 14, 2025, the U.S. Food and Drug Administration (FDA) granted accelerated approval to telisotuzumab vedotin, an antibody–drug conjugate (ADC), for the treatment of adult patients with locally advanced or metastatic non-squamous non–small cell lung cancer (NSCLC) with c-Met overexpression—defined as ≥50% of tumor cells showing strong (3+) staining by immunohistochemistry—who have received at least one prior line of systemic therapy.The approval was based on results from the LUMIN
3 min read
On May 16, 2025, the U.S. Food and Drug Administration (FDA) approved the first blood test designed to aid in the diagnosis of Alzheimer’s disease. The Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio test, developed by Fujirebio Diagnostics, measures the ratio of two plasma proteins — pTau217 and β-amyloid 1-42 — associated with the presence of amyloid plaques in the brain, one of the key biomarkers of the disease.Intended for adults aged 55 and older who present with signs and symptom
IntroductionAn article published in Frontiers in Immunology explores how digital technologies, combined with artificial intelligence (AI) and big data, are revolutionizing the remote monitoring of people with Multiple Sclerosis (MS), a chronic neurodegenerative disease affecting more than 2.8 million people worldwide.MS impairs sensorimotor and cognitive functions, significantly impacting patients’ quality of life. Traditional clinical monitoring, typic
5 min read
Show more
